SIGA Technologies 2025 revenue falls

SIGA Technologies

10/03/2026 20:11

Overview

U.S. infectious disease drugmaker's 2025 revenue and net income fell sharply from prior year

In January 2026, company received $13 mln international order for oral TPOXX

Outlook

SIGA received $13 mln international procurement order for oral TPOXX to be delivered in 2026

Company expects CHMP to confirm positive benefit-risk balance for tecovirimat in March 2026

SIGA focused on securing new procurement contracts with governments to support future revenues

Result Drivers

U.S. PROCUREMENT DROP - Co attributed lower 2025 revenues to reduced procurement orders from U.S. government

DEVELOPMENT FUNDING - Co secured $27 mln in additional U.S. government funding for development activities in 2025

Company press release: ID:nGNX3WGZVj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
$0.32
FY Net Income
$23.3 mln


Analyst Coverage

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)